TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
China Medical System Holdings ( (HK:0867) ) has issued an announcement.
China Medical System Holdings Limited announced positive results from a Phase 3 clinical trial of ruxolitinib cream for treating mild to moderate atopic dermatitis in Chinese patients. The trial demonstrated significant efficacy and safety, with a higher proportion of patients achieving improvement compared to placebo. The company is advancing the new drug application process in China, potentially impacting the treatment landscape for atopic dermatitis, a condition affecting millions in the country.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited is a company involved in the pharmaceutical industry, focusing on innovative skin health products. Its subsidiary, Dermavon Holdings Limited, specializes in developing treatments for dermatological conditions and is seeking a separate listing on the Hong Kong Stock Exchange.
Average Trading Volume: 10,202,535
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.06B
Find detailed analytics on 0867 stock on TipRanks’ Stock Analysis page.